| PD-L1 expression and prognostic impact in glioblastoma EK Nduom, J Wei, NK Yaghi, N Huang, LY Kong, K Gabrusiewicz, X Ling, ... Neuro-oncology 18 (2), 195-205, 2015 | 556 | 2015 |
| Immunosuppressive mechanisms in glioblastoma EK Nduom, M Weller, AB Heimberger Neuro-oncology 17 (suppl_7), vii9-vii14, 2015 | 352 | 2015 |
| MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints J Wei, EK Nduom, LY Kong, Y Hashimoto, S Xu, K Gabrusiewicz, X Ling, ... Neuro-oncology 18 (5), 639-648, 2016 | 179 | 2016 |
| Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma S Xu, J Wei, F Wang, LY Kong, XY Ling, E Nduom, K Gabrusiewicz, ... Journal of the National Cancer Institute 106 (8), dju162, 2014 | 136 | 2014 |
| Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms EK Nduom, C Yang, MJ Merrill, Z Zhuang, RR Lonser Journal of neurosurgery 119 (2), 427-433, 2013 | 126 | 2013 |
| Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment EKE Nduom, CG Hadjipanayis, EG Van Meir The Cancer Journal 18 (1), 100-106, 2012 | 84 | 2012 |
| Acute lung injury is an independent risk factor for brain hypoxia after severe traumatic brain injury M Oddo, E Nduom, S Frangos, L MacKenzie, I Chen, E Maloney-Wilensky, ... Neurosurgery 67 (2), 338-344, 2010 | 74 | 2010 |
| The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma S Jackson, J Weingart, EK Nduom, TT Harfi, RT George, D McAreavey, ... Fluids and Barriers of the CNS 15, 1-9, 2018 | 64 | 2018 |
| Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases S Ranjan, M Quezado, N Garren, L Boris, C Siegel, O Lopes Abath Neto, ... BMC cancer 18, 1-9, 2018 | 57 | 2018 |
| Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK AJ Giles, S Hao, M Padget, H Song, W Zhang, J Lynes, V Sanchez, Y Liu, ... JCI insight 4 (20), 2019 | 46 | 2019 |
| Immune modulatory nanoparticle therapeutics for intracerebral glioma NK Yaghi, J Wei, Y Hashimoto, LY Kong, K Gabrusiewicz, EK Nduom, ... Neuro-oncology 19 (3), 372-382, 2017 | 44 | 2017 |
| Canine model of convection-enhanced delivery of cetuximab-conjugated iron-oxide nanoparticles monitored with magnetic resonance imaging S Platt, E Nduom, M Kent, C Freeman, R Machaidze, M Kaluzova, L Wang, ... Neurosurgery 59, 107-113, 2012 | 43 | 2012 |
| Nanotechnology applications for glioblastoma EK Nduom, A Bouras, M Kaluzova, CG Hadjipanayis Neurosurgery Clinics of North America 23 (3), 439-449, 2012 | 41 | 2012 |
| Biomarkers for immunotherapy for treatment of glioblastoma JP Lynes, AK Nwankwo, HP Sur, VE Sanchez, KA Sarpong, OI Ariyo, ... Journal for immunotherapy of cancer 8 (1), 2020 | 40 | 2020 |
| Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases LJ Sudmeier, KB Hoang, EK Nduom, A Wieland, SG Neill, ... Cell Reports Medicine 3 (5), 2022 | 33 | 2022 |
| Cytokine microdialysis for real-time immune monitoring in glioblastoma patients undergoing checkpoint blockade J Lynes, S Jackson, V Sanchez, G Dominah, X Wang, A Kuek, CP Hayes, ... Neurosurgery 84 (4), 945-953, 2019 | 32 | 2019 |
| GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models VE Sanchez, JP Lynes, S Walbridge, X Wang, NA Edwards, AK Nwankwo, ... Scientific Reports 10 (1), 11003, 2020 | 31 | 2020 |
| Current options and future directions in immune therapy for glioblastoma J Lynes, V Sanchez, G Dominah, A Nwankwo, E Nduom Frontiers in oncology 8, 578, 2018 | 31 | 2018 |
| Programmed death ligand 1 is a negative prognostic marker in recurrent isocitrate dehydrogenase-wildtype glioblastoma D Pratt, G Dominah, G Lobel, A Obungu, J Lynes, V Sanchez, ... Neurosurgery 85 (2), 280-289, 2019 | 26 | 2019 |
| Imaging detection of endolymphatic sac tumor–associated hydrops JA Butman, E Nduom, HJ Kim, RR Lonser Journal of Neurosurgery 119 (2), 406-411, 2013 | 26 | 2013 |
Konrad Ryszard GabrusiewiczCellis AGVerified email at cellis.eu
